KR20190013831A - T 세포 증식 - Google Patents

T 세포 증식 Download PDF

Info

Publication number
KR20190013831A
KR20190013831A KR1020187036135A KR20187036135A KR20190013831A KR 20190013831 A KR20190013831 A KR 20190013831A KR 1020187036135 A KR1020187036135 A KR 1020187036135A KR 20187036135 A KR20187036135 A KR 20187036135A KR 20190013831 A KR20190013831 A KR 20190013831A
Authority
KR
South Korea
Prior art keywords
cells
medium
virus
cell
population
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020187036135A
Other languages
English (en)
Korean (ko)
Inventor
피터 왕
춘시아오 우
Original Assignee
테사 테라퓨틱스 피티이. 엘티디.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 테사 테라퓨틱스 피티이. 엘티디. filed Critical 테사 테라퓨틱스 피티이. 엘티디.
Publication of KR20190013831A publication Critical patent/KR20190013831A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1107—B cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Developmental Biology & Embryology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
KR1020187036135A 2016-05-24 2016-10-25 T 세포 증식 Withdrawn KR20190013831A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662340605P 2016-05-24 2016-05-24
US62/340,605 2016-05-24
US15/290,230 2016-10-11
US15/290,230 US10052372B2 (en) 2016-05-24 2016-10-11 T cell expansion
PCT/EP2016/075644 WO2017202478A1 (en) 2016-05-24 2016-10-25 T cell expansion

Publications (1)

Publication Number Publication Date
KR20190013831A true KR20190013831A (ko) 2019-02-11

Family

ID=57886334

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187036135A Withdrawn KR20190013831A (ko) 2016-05-24 2016-10-25 T 세포 증식

Country Status (12)

Country Link
US (2) US10052372B2 (https=)
EP (1) EP3265555B1 (https=)
JP (1) JP2019520061A (https=)
KR (1) KR20190013831A (https=)
CN (1) CN109563483A (https=)
DK (1) DK3265555T3 (https=)
ES (1) ES2742215T3 (https=)
HK (1) HK1250378B (https=)
PT (1) PT3265555T (https=)
SG (1) SG11201810471YA (https=)
TW (1) TWI660970B (https=)
WO (1) WO2017202478A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6250628B2 (ja) * 2012-03-20 2017-12-20 イーグル・ファーマシューティカルズ・インコーポレーテッド ベンダムスチンの製剤
JP6987080B2 (ja) 2016-05-05 2021-12-22 サウスウェスト リサーチ インスティテュート 細胞増殖のための三次元バイオリアクター及び関連用途
US10052372B2 (en) * 2016-05-24 2018-08-21 Tessa Therapeutics Pte Ltd T cell expansion
EP3621340B1 (en) * 2017-05-06 2021-10-20 LG Electronics Inc. Transmission of channel quality information
EP3723774A4 (en) * 2017-12-15 2021-09-08 The Board of Trustees of the Leland Stanford Junior University COMPOSITIONS AND METHODS OF INHIBITION OF T-CELL EXHAUSTATION
US11149244B2 (en) 2018-04-04 2021-10-19 Southwest Research Institute Three-dimensional bioreactor for T-cell activation and expansion for immunotherapy
JP7376576B2 (ja) 2018-09-24 2023-11-08 サウスウェスト リサーチ インスティテュート 三次元バイオリアクター
WO2021221927A1 (en) 2020-04-27 2021-11-04 Parsons Corporation Narrowband iq signal obfuscation
WO2022197933A1 (en) 2021-03-18 2022-09-22 The Broad Institute, Inc. Compositions and methods for characterizing lymphoma and related conditions
CN117529551A (zh) 2021-04-27 2024-02-06 贝勒医学院 表达嵌合抗原受体的病毒特异性免疫细胞
AU2022377625B2 (en) 2021-10-28 2025-01-02 Southwest Research Institute Devices for cell separation
TW202346576A (zh) 2022-04-13 2023-12-01 新加坡商泰莎治療有限公司 治療性t細胞產品

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962318A (en) * 1996-11-15 1999-10-05 St. Jude Children's Research Hospital Cytotoxic T lymphocyte-mediated immunotherapy
AU1220599A (en) 1997-11-14 1999-06-07 Hemosol Inc. Method for the production and use of dendritic cells
WO2003012085A1 (en) * 2001-07-30 2003-02-13 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Antigen presenting cells, method for their preparation and their use for cancer vaccines
US7651855B2 (en) * 2003-04-17 2010-01-26 The Trustees Of The University Of Pennsylvania Regulatory T cells and their use in immunotherapy and suppression of autoimmune responses
EP2510086A4 (en) * 2009-12-08 2013-05-22 Wolf Wilson Mfg Corp IMPROVED METHODS FOR CELL CULTURES FOR ADOPTIVE CELL THERAPIES
KR101749195B1 (ko) * 2011-12-12 2017-06-20 셀 메디카 리미티드 T 세포들을 증식시키는 방법
JP6327734B2 (ja) * 2012-03-07 2018-05-23 国立大学法人富山大学 Ｔ細胞の刺激方法およびその利用
US10052372B2 (en) * 2016-05-24 2018-08-21 Tessa Therapeutics Pte Ltd T cell expansion

Also Published As

Publication number Publication date
DK3265555T3 (da) 2019-08-12
TW201741330A (zh) 2017-12-01
PT3265555T (pt) 2019-09-04
SG11201810471YA (en) 2018-12-28
WO2017202478A1 (en) 2017-11-30
EP3265555A1 (en) 2018-01-10
EP3265555B1 (en) 2019-05-22
ES2742215T3 (es) 2020-02-13
TWI660970B (zh) 2019-06-01
US20190269768A1 (en) 2019-09-05
US10052372B2 (en) 2018-08-21
CN109563483A (zh) 2019-04-02
HK1250378B (en) 2020-05-08
JP2019520061A (ja) 2019-07-18
US20170028042A1 (en) 2017-02-02

Similar Documents

Publication Publication Date Title
KR20190013831A (ko) T 세포 증식
US10577586B2 (en) Compositions and methods for modulating an immune response
JP6445437B2 (ja) Ｂ細胞の増加及び評価方法並びに疾患治療のための増加ｂ細胞の使用方法
HK1250378A1 (en) T cell expansion
US8221741B2 (en) Methods for modulating inflammatory and/or immune responses
US20070098734A1 (en) Ex-vivo priming for generating cytotoxic T lymphocytes specific for non-tumor antigens to treat autoimmune and allergic disease
KR101867942B1 (ko) 바이러스 항원 특이적인 t 세포의 유도 및 증식 방법
JP2000509604A (ja) サプレッサー細胞集団を生成するためのインターロイキン―１０の使用
JP2013523886A (ja) 制御性ｔ細胞の阻害のための方法および組成物
US9173908B2 (en) Methods for modulating immune responses
WO2005078072A1 (ja) Ｔ細胞免疫活性を調節する制御性細胞
EP4457238A1 (en) Polydonor cd4t cells expressing il-10 and uses thereof
CN117604011A (zh) 融合基因、表达该融合基因的滋养型树突状细胞、自然杀伤细胞培养方法以及自然杀伤细胞

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20181212

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid